Trial
NCT04697069
A Study to Evaluate of the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Acneiform Rash
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Vanda Pharmaceuticals
Collaborators
—
Condition
Acneiform Eruptions
Intervention
Imsidolimab
Why stopped
Administrative Reason
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-09-22